High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)

高剂量与低剂量泼尼松龙治疗 COVID-19 后弥漫性实质性肺异常症状患者的疗效比较：一项开放标签随机试验（COLDSTER 试验）

阅读：2
作者：Dhooria,Sahajal,Chaudhary,Shivani,Sehgal,Inderpaul Singh,Agarwal,Ritesh,Arora,Siddhant,Garg,Mandeep,Prabhakar,Nidhi,Puri,Goverdhan Dutt,Bhalla,Ashish,Suri,Vikas,Yaddanapudi,Lakshmi Narayana,Muthu,Valliappan,Prasad,Kuruswamy Thurai,Aggarwal,Ashutosh Nath
期刊：European Respiratory Journal影响因子：21.000
时间：2022起止号：2022 Feb;59(2)
doi：10.1183/13993003.02930-2021靶点： COL

Abstract

High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。